Glenmark Life Sciences has announced its financial results for the second quarter of fiscal year 2025, reporting a decline in both revenue and net profit compared to the same period last year. The company’s revenue from operations for Q2 FY25 stood at ₹506.88 crore, down 15% year-on-year (YoY) from ₹595.36 crore in Q2 FY24. Meanwhile, net profit for the quarter fell by 20% YoY to ₹95.32 crore from ₹118.74 crore in the same quarter of the previous year.
Key Financial Highlights:
- Revenue from Operations: Glenmark Life Sciences generated ₹506.88 crore in revenue during Q2 FY25, reflecting a 15% decline from ₹595.36 crore in Q2 FY24. On a sequential basis, revenue also dropped from ₹588.62 crore in Q1 FY25.
- Net Profit: The company’s net profit for Q2 FY25 stood at ₹95.32 crore, a 20% decrease compared to ₹118.74 crore in the same quarter last year. Net profit also declined from ₹111.48 crore in Q1 FY25.
Half-Year Performance:
For the first half of FY25, Glenmark Life Sciences recorded a total revenue of ₹1,095.50 crore, down from ₹1,173.81 crore in the same period last year. The net profit for H1 FY25 stood at ₹206.80 crore, compared to ₹254.19 crore in H1 FY24.
The company faced challenges in both revenue generation and profitability in Q2 FY25, with significant YoY declines. However, Glenmark Life Sciences continues to focus on operational efficiency and product portfolio expansion to navigate these challenges and improve its performance in the coming quarters.
